Evidence map›Paper›PMID 34163014›Full record

ArticleBone marrow transplantation2021

Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma.

Christopher Lemieux, Lori S Muffly, David J Iberri, Juliana K Craig, Laura J Johnston, Robert Lowsky, Parveen Shiraz, Andrew R Rezvani, Matthew J Frank, Wen-Kai Weng and 7 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone marrow transplantation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Christopher LemieuxDepartment of Medicine, Stanford University, Stanford, CA, USA.
Lori S MufflyDepartment of Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-9887-6136
David J IberriDepartment of Medicine, Stanford University, Stanford, CA, USA.
Juliana K CraigDepartment of Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-5644-2292
Laura J JohnstonDepartment of Medicine, Stanford University, Stanford, CA, USA.
Robert LowskyDepartment of Medicine, Stanford University, Stanford, CA, USA.
Parveen ShirazDepartment of Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-6721-0358
Andrew R RezvaniDepartment of Medicine, Stanford University, Stanford, CA, USA.
Matthew J FrankDepartment of Medicine, Stanford University, Stanford, CA, USA.
Wen-Kai WengDepartment of Medicine, Stanford University, Stanford, CA, USA.
Everett MeyerDepartment of Medicine, Stanford University, Stanford, CA, USA.
Judith A ShizuruDepartment of Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-3246-4726
Sally AraiDepartment of Medicine, Stanford University, Stanford, CA, USA.
Michaela LiedtkeDepartment of Medicine, Stanford University, Stanford, CA, USA.
Robert S NegrinDepartment of Medicine, Stanford University, Stanford, CA, USA.
David B MiklosDepartment of Medicine, Stanford University, Stanford, CA, USA.
Surbhi SidanaDepartment of Medicine, Stanford University, Stanford, CA, USA. Surbhi.sidana@stanford.edu.ORCID http://orcid.org/0000-0003-3288-7614
Stanford University · USStanford Medicine · USUniversité Laval · CA

Funding

Institutional Career Development Core (KL2)KL2TR003143 · NCATS · STANFORD UNIVERSITY · PI ASCH, STEVEN M. · 2019 to 2023
$8.7M
NCATS NIH HHS KL2 TR003143
6 · The paper itself

Abstract

We evaluated the outcomes of 168 patients undergoing delayed or second autologous stem cell transplant (ASCT) for relapsed multiple myeloma (MM) from 2010 to 2019. Overall, 21% (n = 35) patients had received a prior transplant and 69% (n = 116) underwent transplant at first relapse. Overall, 27% patients had high-risk cytogenetics and 15% had ISS stage III disease. Stem cell collection was performed after relapse in 72% and 35% of patients received maintenance therapy. Median PFS from salvage treatment and transplant were 28 and 19 months, respectively. Median OS from salvage treatment and transplant was 69 and 55 months. Multivariate analysis revealed that ASCT in first relapse was associated with superior PFS (HR 0.63, p = 0.03) and OS (HR 0.59, p = 0.04) compared to later lines of therapy. In addition, PFS of ≥36 months with prior therapy was associated with improved PFS (HR 0.62, p = 0.04) and OS (HR 0.41, p = 0.01). Ninety-five patients underwent delayed transplant at first relapse, median PFS and OS from start of therapy was 30 and 69 months, and median OS from diagnosis was 106 months. These data may serve as a guide when counseling patients undergoing ASCT for relapsed MM and provide a benchmark in designing clinical trials of transplantation/comparative treatments for relapsed MM.

Indexed as

Hematopoietic Stem Cell TransplantationMultiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsDisease-Free SurvivalHumansNeoplasm Recurrence, LocalRetrospective StudiesSalvage TherapyTransplantation, Autologous

Identifiers

PMID34163014
PMCPMC8715953
OpenAlexW3173193747

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.